Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY22 results · Jul–Sep 2021
Lincoln Pharmaceuticals reported revenue from operations of ₹125.64 crore (up 2.7% from Q2 FY21) and net profit of ₹22.88 crore (up 13.3% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a standalone basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 125.64 | 122.29 | +2.7% | 119.74 | +4.9% |
| Other income | 3.77 | 1.22 | +209.4% | 2.32 | +62.5% |
| Total income | 129.41 | 123.51 | +4.8% | 122.06 | +6.0% |
| Profit before tax | 30.24 | 27.39 | +10.4% | 24.49 | +23.4% |
| Net profit for the period | 22.88 | 20.20 | +13.3% | 17.38 | +31.7% |
| EPS, basic (₹) | 11.44 | 10.10 | +13.3% | 8.69 | +31.6% |
| Net margin (%) | 18.2 | 16.5 | 14.5 |
Standalone
- Filed with BSE
- 11 Nov 2021, 17:56 IST
- Board meeting
- 11 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE